Amneal Pharmaceuticals IncAMRX
Price$20.14Intrinsic value$14.1430% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.1B+11.6% YoYTTM through 30 Jun 2026
Net Income $157.4MTTM through 30 Jun 2026
Free Cash Flow $127.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin44.3%
EBITDA Margin21.1%
Operating Margin19.6%
Net Margin5.1%

Returns

-265.5%ROE
3.5%ROA
6.4%ROIC

Balance Sheet Health

Debt / Equity-58.47x
Current Ratio1.45x
Net Debt$2.5B
Cash & Equivalents$127.6M

Quality Metrics

Altman Z-Score2.49
Piotroski F-Score7 / 9
FCF Margin4.1%
Rule of 405.1
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $3B
Diluted EPS$0.48TTM
'19'20'21'22'23'24'25
FY2025: $0.22

Dividend

No dividend

Capital Allocation

R&D Spend$175.6M
Capex Intensity2.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.